Abstract
Remifentanil pre-treatment has been reported to decrease the incidence of rocuronium injection-associated withdrawal movement. This study was designed to explore the site of action of remifentanil for reducing withdrawal response during rocuronium injection in children. Ninety-six paediatric patients were randomly assigned to three groups. After induction of anaesthesia with 5 mg/kg 2.5% thiopental sodium, 2 ml saline (placebo group) or 0.5 μg/kg remifentanil (group R), was injected intravenously 1 min before 0.6 mg/kg rocuronium. In a third group(group R′), the venous retention of 0.5 μg/kg remifentanil was maintained for 30 s followed by tourniquet release and injection of 0.6 mg/kg rocuronium. Withdrawal response was graded using a four-point scale. The incidence of withdrawal movement after rocuronium administration was 94%, 22% and 81% in the placebo, R, and R′ groups, respectively. This study demonstrated that the pre-treatment effect of remifentanil for reducing rocuronium-associated withdrawal response occurs mainly through a central action.
| Original language | English |
|---|---|
| Pages (from-to) | 1795-1800 |
| Number of pages | 6 |
| Journal | Journal of International Medical Research |
| Volume | 38 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2010 Jan 1 |
Fingerprint
Keywords
- Children
- Pain
- Remifentanil
- Rocuronium
- Withdrawal response
ASJC Scopus subject areas
- Biochemistry
- Cell Biology
- Biochemistry, medical
Cite this
The analgesic effect of remifentanil on prevention of withdrawal response associated with the injection of rocuronium in children : No evidence for a peripheral action. / Yoon, J. R.; Jeon, Y.; Yoo, Young; Shin, H. J.; Ahn, J. H.; Lim, Choon Hak.
In: Journal of International Medical Research, Vol. 38, No. 5, 01.01.2010, p. 1795-1800.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The analgesic effect of remifentanil on prevention of withdrawal response associated with the injection of rocuronium in children
T2 - No evidence for a peripheral action
AU - Yoon, J. R.
AU - Jeon, Y.
AU - Yoo, Young
AU - Shin, H. J.
AU - Ahn, J. H.
AU - Lim, Choon Hak
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Remifentanil pre-treatment has been reported to decrease the incidence of rocuronium injection-associated withdrawal movement. This study was designed to explore the site of action of remifentanil for reducing withdrawal response during rocuronium injection in children. Ninety-six paediatric patients were randomly assigned to three groups. After induction of anaesthesia with 5 mg/kg 2.5% thiopental sodium, 2 ml saline (placebo group) or 0.5 μg/kg remifentanil (group R), was injected intravenously 1 min before 0.6 mg/kg rocuronium. In a third group(group R′), the venous retention of 0.5 μg/kg remifentanil was maintained for 30 s followed by tourniquet release and injection of 0.6 mg/kg rocuronium. Withdrawal response was graded using a four-point scale. The incidence of withdrawal movement after rocuronium administration was 94%, 22% and 81% in the placebo, R, and R′ groups, respectively. This study demonstrated that the pre-treatment effect of remifentanil for reducing rocuronium-associated withdrawal response occurs mainly through a central action.
AB - Remifentanil pre-treatment has been reported to decrease the incidence of rocuronium injection-associated withdrawal movement. This study was designed to explore the site of action of remifentanil for reducing withdrawal response during rocuronium injection in children. Ninety-six paediatric patients were randomly assigned to three groups. After induction of anaesthesia with 5 mg/kg 2.5% thiopental sodium, 2 ml saline (placebo group) or 0.5 μg/kg remifentanil (group R), was injected intravenously 1 min before 0.6 mg/kg rocuronium. In a third group(group R′), the venous retention of 0.5 μg/kg remifentanil was maintained for 30 s followed by tourniquet release and injection of 0.6 mg/kg rocuronium. Withdrawal response was graded using a four-point scale. The incidence of withdrawal movement after rocuronium administration was 94%, 22% and 81% in the placebo, R, and R′ groups, respectively. This study demonstrated that the pre-treatment effect of remifentanil for reducing rocuronium-associated withdrawal response occurs mainly through a central action.
KW - Children
KW - Pain
KW - Remifentanil
KW - Rocuronium
KW - Withdrawal response
UR - http://www.scopus.com/inward/record.url?scp=78449302704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78449302704&partnerID=8YFLogxK
U2 - 10.1177/147323001003800526
DO - 10.1177/147323001003800526
M3 - Article
VL - 38
SP - 1795
EP - 1800
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 0300-0605
IS - 5
ER -